Mesoblast's Ryoncil Awaits FDA Approval for SR-aGVHD
FDA has accepted Mesoblast's (mesoblast) application for the market authorization of its off-the-shelf cell therapy.
FDA accepts the application for the listing of Mesoblast's (mesoblast) spot-specific cell therapy.
Express News | Mesoblast Ltd : Piper Sandler Raises to Overweight From Neutral; Raises Target Price to $11 From $4
FDA Accepts Mesoblast's Latest BLA for Paediatric GvHD Cell Therapy
Mesoblast Raised to Overweight From Neutral by Piper Sandler
Mesoblast Price Target Raised to $11.00/Share From $4.00 by Piper Sandler
Mesoblast Analyst Ratings
Piper Sandler Upgrades Mesoblast(MESO.US) to Buy Rating
Regulatory Approval Drives Sharp Increase In Mesoblast (MESO) Shares
Danaher Posts Upbeat Earnings, Joins Spotify, MSCI, Owens & Minor And Other Big Stocks Moving Higher On Tuesday
Mesoblast's Gets FDA Acceptance of Application for Allogeneic Cellular Therapy
TransCode RNAZ Offering; Mesoblast MESO BLA Resubmission Accepted
Express News | Mesoblast Shares Are Trading Higher After the Company Announced That the FDA Accepted Its Biologics License Application Resubmission for Ryoncil in the Treatment of Children With Steroid-refractory Acute Graft Versus Host Disease
Express News | FDA Accepts Mesoblast's Biologics License Application (BLA) For Ryoncil In Children With Steroid-Refractory Acute Graft-Versus-Host Disease
Top Premarket Gainers
Mesoblast Shares Rise on Start of Late-Stage Trial For Low Back Pain Treatment
Why SAP Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Mesoblast's Ryoncil Awaits FDA Approval for Pediatric Use
Express News | Mesoblast - US FDA Accepts Mesoblast's Bla Resubmission for Remestemcel-L
Express News | Reported Sunday, Mesoblast Begins Enrollment In Phase 3 Trial Of Rexlemestrocel-L For Chronic Low Back Pain
No Data